中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2014年
33期
5402-5406
,共5页
组织构建%骨组织工程%质子泵抑制剂%H2受体拮抗剂%奥美拉唑%骨折风险%骨密度
組織構建%骨組織工程%質子泵抑製劑%H2受體拮抗劑%奧美拉唑%骨摺風險%骨密度
조직구건%골조직공정%질자빙억제제%H2수체길항제%오미랍서%골절풍험%골밀도
acid-suppressive medication%fracture risk%meta-analysis
背景：3年以上长期使用抑酸剂者是否会增加骨折的风险度，一直以来都是争议的焦点。<br> 目的：系统评价使用抑酸剂(包括质子泵抑制剂和H2受体拮抗剂)对骨质疏松性骨折的影响。<br> 方法：计算机检索MEDLINE、Cochrane、Embase、CNKI数字图书馆等数据库，并手工检索查找有关研究使用抑酸剂和骨折风险度之间关联性的临床试验研究。由2名评价员独立筛查试验、提取资料和评估方法学质量，采用Cochrane协作网提供的RevMan 5.0软件进行Meta分析。<br> 结果与结论：纳入11篇文献进行荟萃分析，3篇为队列研究，5篇为病例-对照研究，3篇为组内病例对照研究。使用质子泵抑制剂对骨折风险度的影响有统计学意义[OR=1.29，95%CI(1.18，1.41)，P<0.001]，而使用H2受体拮抗剂对骨折风险度的影响无统计学意义[OR=1.10，95%CI(0.99，1.23)，P=0.34]。长期使用质子泵抑制剂将使骨折风险度显著增高，该效应对于患骨质疏松症的老年人群尤为明显。
揹景：3年以上長期使用抑痠劑者是否會增加骨摺的風險度，一直以來都是爭議的焦點。<br> 目的：繫統評價使用抑痠劑(包括質子泵抑製劑和H2受體拮抗劑)對骨質疏鬆性骨摺的影響。<br> 方法：計算機檢索MEDLINE、Cochrane、Embase、CNKI數字圖書館等數據庫，併手工檢索查找有關研究使用抑痠劑和骨摺風險度之間關聯性的臨床試驗研究。由2名評價員獨立篩查試驗、提取資料和評估方法學質量，採用Cochrane協作網提供的RevMan 5.0軟件進行Meta分析。<br> 結果與結論：納入11篇文獻進行薈萃分析，3篇為隊列研究，5篇為病例-對照研究，3篇為組內病例對照研究。使用質子泵抑製劑對骨摺風險度的影響有統計學意義[OR=1.29，95%CI(1.18，1.41)，P<0.001]，而使用H2受體拮抗劑對骨摺風險度的影響無統計學意義[OR=1.10，95%CI(0.99，1.23)，P=0.34]。長期使用質子泵抑製劑將使骨摺風險度顯著增高，該效應對于患骨質疏鬆癥的老年人群尤為明顯。
배경：3년이상장기사용억산제자시부회증가골절적풍험도，일직이래도시쟁의적초점。<br> 목적：계통평개사용억산제(포괄질자빙억제제화H2수체길항제)대골질소송성골절적영향。<br> 방법：계산궤검색MEDLINE、Cochrane、Embase、CNKI수자도서관등수거고，병수공검색사조유관연구사용억산제화골절풍험도지간관련성적림상시험연구。유2명평개원독립사사시험、제취자료화평고방법학질량，채용Cochrane협작망제공적RevMan 5.0연건진행Meta분석。<br> 결과여결론：납입11편문헌진행회췌분석，3편위대렬연구，5편위병례-대조연구，3편위조내병례대조연구。사용질자빙억제제대골절풍험도적영향유통계학의의[OR=1.29，95%CI(1.18，1.41)，P<0.001]，이사용H2수체길항제대골절풍험도적영향무통계학의의[OR=1.10，95%CI(0.99，1.23)，P=0.34]。장기사용질자빙억제제장사골절풍험도현저증고，해효응대우환골질소송증적노년인군우위명현。
BACKGROUND:Whether a long-term use of acid-suppressive medication for over 3 years can increase the risk of fractures, remains controversial. <br> OBJECTIVE:To systematical y review the effect of acid-suppressive medication on fracture risk. <br> METHODS:Clinical trials about the relationship of acid-suppressive medication use and risk of osteoporosis-related fractures were searched in MEDLINE, Cochrane Library, EMbase, and CNKI database. We also manual y searched some published and unpublished references. Study selection and assessment, data col ection and analyses were undertaken by two reviewers independently. The Cochrane Col aboration’s RevMan 5.0 software was used for data analyses. <br> RESULTS AND CONCLUSION:After a comprehensive search, 11 original clinical trials were included in this meta-analysis, including 3 nested case-control studies, 5 case-control studies, and 3 cohort studies. Patients with fractures were more likely than controls to have previously received supply of proton pump inhibitors [odds ratio (OR)=1.29, 95%confidence interval (CI) (1.18-1.41), P<0.001]. The meta-analysis did not find a significant difference in the patients who received H2 receptor antagonists [OR=1.10, 95%CI (0.99-1.23), P=0.34]. A long-term use of proton pump inhibitors is associated with an increased risk of fracture in elderly persons already at a risk for osteoporosis.
